Évolution des indications cliniques en hadronthérapie 2008–2012

Habrand, Jean‐Louis; Datchary, Jean; Alapetite, Claire; Bolle, Stéphanie; Calugaru, Valentin; Feuvret, L.; Helfre, Sylvie; Stefan, Daniela Cristina; Delacroix, S.; Demarzi, L.; Dendale, R.

doi:10.1016/j.canrad.2013.07.141

Cited by 8 publications

(3 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The rationale for hadron therapy with protons and carbon ions stems from ballistic properties that allow precise targeting of tumor volume while preserving healthy tissue [7]. With regard to metastatic disease, the efficacy data with regard to chemotherapy, mainly come from small series of phase 2 studies that included adenoid cystic carcinoma of the head and neck, in the global sense.…”

Section: Discussionmentioning

confidence: 99%

"Nasopharynaeal Adenoid Cystic Carcinoma, A Rare Disease: A Case Report and Review of Literature"

Bechairia

2023

BJSTR

View full text Add to dashboard Cite

Nasopharyngeal adenoid cystic carcinoma is a rare tumor. Compared with other nasopharyngeal tumors, it is characterized by slow evolution but is locally aggressive and has a high tendency to recurrence. Due to the rarity of cases, no consensus exists about treatment approaches. We report the case of 42-year-old man with a locally advanced adenoid cystic carcinoma. The patient received concurrent chemoradiation and had a good objective response. After one year, he developed lung metastasis and received platinbased chemotherapy. The aim of this work is to review the literature concerning this rare malignancy and discusses treatment approaches, both for initial management and locoregional/metastatic relapses.

show abstract

Section: Discussionmentioning

confidence: 99%

"Nasopharynaeal Adenoid Cystic Carcinoma, A Rare Disease: A Case Report and Review of Literature"

Bechairia

2023

BJSTR

View full text Add to dashboard Cite

show abstract

“…Parallèlement à cet essor scientifique, de la protonthéra-pie, le nombre d'installations d'accélérateurs a considérablement augmenté, tant en Amérique du Nord (14 installations) qu'en Europe (15 installations) et en Asie (15 installations) [3,4].…”

Section: Protonthérapie Nationale Et Internationaleunclassified

“…Des études doivent être réalisées pour permettre une escalade de dose. Un essai de phase III est en cours aux États-Unis afin de comparer à doses équivalentes (50,4 Gy) une irradiation par protons et une RCMI par photons (NCT01512589, objectif primaire : survie sans progression) dans les cancers de l'estomac et de l'oesophage relevant d'une radiothérapie, non métastatiques.…”

Section: Carcinomes Oesophagiens/estomacunclassified